Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.